SCHEMBL13650570

SCHEMBL13650570

Nc1nc(N[C@H]2CC[C@H](N3CCCC3)CC2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 3/20 0.49
▸ HRH3 Q9Y5N1 3/20 0.49
▸ CCR4 P51679 2/20 0.41
▸ SIGMAR1 Q99720 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.38
▸ BTK Q06187 2/20 0.37
▸ HRH2 P25021 1/20 0.37
▸ DRD2 P14416 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ MERTK Q12866 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ ATAD2 Q6PL18 1/20 0.34
▸ NUDT1 P36639 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ PSEN1 P49768 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13654554 0.92 HRH4 (0.49) HRH4HRH3CCR4SIGMAR1CYP2D6
SCHEMBL13650547 0.85 HRH3 (0.48) HRH4HRH3BTKHRH2ACHE
SCHEMBL13650572 0.83 HRH3 (0.46) HRH4HRH3SIGMAR1CYP2D6CYP2C19
SCHEMBL13650553 0.83 HRH3 (0.46) HRH4HRH3BTKHRH2MERTK
SCHEMBL13650569 0.82 HRH3 (0.47) HRH4HRH3SIGMAR1HRH2DRD2
SCHEMBL13650549 0.82 HRH4 (0.45) HRH4HRH3BTKHRH2IRAK4
SCHEMBL13650551 0.81 HRH3 (0.47) HRH4HRH3BTKHRH2BRD4
SCHEMBL13650508 0.81 HRH3 (0.68) HRH4HRH3CCR4CYP2D6CYP2C19
SCHEMBL13650640 0.79 HRH4 (0.69) HRH4HRH3CYP2D6CYP2C19TLR7
SCHEMBL13650568 0.79 HRH3 (0.49) HRH4HRH3HRH2MERTKACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885CCR4 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback